Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC). [NA]
An ongoing clinical trial is examining complications associated with lymphadenectomy in the surgical treatment of advanced non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC [Phase 2]
A Phase 2 neoadjuvant trial is comparing Serplulimab to Nivolumab in resectable stage II-IIIA squamous non-small cell lung cancer, and recru…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase [NA]
This clinical trial examines whether respiratory rehabilitation improves quality of life for patients with metastatic non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer [Phase 2]
Phase 2 study of tislelizumab monotherapy and tislelizumab-based combinations in resectable non-small cell lung cancer. The update reports o…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NT-I7 (efineptakin alfa) in combination with pembrolizumab in adults with advanced solid tumors has completed and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer [Phase 1, Phase 2]
This completed open-label Phase 1/2 trial evaluated the combination of Itacitinib and Osimertinib in subjects with non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors [Phase 2]
A Phase 2 study evaluating vobramitamab duocarmazine in metastatic castration-resistant prostate cancer and other solid tumors was terminate…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 [Phase 1]
A Phase 1 clinical trial is investigating pembrolizumab in combination with a single-agent chemotherapy as first-line treatment for locally …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 trial update of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy, being studied in advanced or metastatic solid tumors. The study is …
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1]
A Phase 1 clinical trial evaluating radiation therapy to relieve symptoms in patients with advanced Non-Small Cell Lung Cancer has completed…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
A prospective cohort study evaluating Zorifertinib as first-line therapy for EGFR-mutant advanced non-small cell lung cancer with brain/CNS …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer [Phase 2]
This clinical trial update describes a Phase 2 neoadjuvant study of lazertinib, with or without chemotherapy, in patients with EGFR-mutated …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC [Phase 1]
Phase 1 trial investigating ceritinib in combination with docetaxel for ALK-negative, EGFR wild-type advanced non-small cell lung cancer; th…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating risk-adapted, proteomic-guided systemic therapy for previously untreated, advanced non-small cell lung can…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC [Phase 2]
Phase 2 clinical trial evaluating the combination of immunotherapy, chemotherapy, radiotherapy, and surgery for patients with synchronous ol…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) [Phase 2]
Phase 2 BEAT trial compares atezolizumab alone versus atezolizumab plus bevacizumab as first-line therapy in non-small cell lung cancer; the…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
A clinical trial at Abramson Cancer Center investigates the effects of immune checkpoint inhibitors on the coronary microvasculature, with a…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases [Phase 2]
Phase 2 trial update on the efficacy and safety of trastuzumab deruxtecan (Enhertu) in HER2-mutant advanced non-small cell lung cancer, incl…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: GCC 2546- Motion Management [NA]
Clinical trial entry GCC 2546- Motion Management is not yet recruiting for non-small cell lung cancer, with radiation as part of the conditi…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) [NA]
The FEED Trial is investigating a high-fermented food intervention in patients with rectal cancer (also listed for non-small cell lung cance…
-
CLINICAL_TRIALS other · 2026-02-09Clinical Trial Update: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study of IDE161, a PARG inhibitor, is recruiting in patients with several solid tumor types including breast, ovarian, and various l…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Intratumoral Cisplatin for Resectable NSCLC [Phase 1]
Phase 1 trial evaluating intratumoral cisplatin in patients with resectable non-small cell lung cancer has completed and results have been p…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) [Phase 2]
Phase 2 expanded Lung-MAP trial evaluating treatment for advanced non-small cell lung cancer with actionable genomic alterations after prior…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
Completed clinical trial investigating predictive immune biomarkers for atezolizumab therapy in patients with non-small cell lung cancer.